Advertisement

Taxanes in Combined Modality Therapy

  • Robert M. MacRae
  • Hak Choy
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

The taxanes are a relatively new group of plant-derived chemotherapeutic agents that have been studied quite extensively in both preclinical studies and in clinical trials. This group of drugs, which includes paclitaxel (Taxol) and docetaxel (Taxotere), act as mitotic spindle inhibitors through their promotion of microtubule assembly and retardation of disaggregation. Paclitaxel is a natural product derived from the bark of the Pacific yew (Taxus brevifolia) whereas taxotere is a semisynthetic analog prepared from the needles of the European yew (Taxus baccata) (1). The taxanes as a group have had significant success in the treatment of solid tumors in the setting of both metastatic disease and adjuvant therapy as well as in locally advanced disease where they are combined with radiation in either a sequential or concurrent fashion. There are also several newer taxanes/microtubule inhibitors that are under development that appear to have promising activities in the completed preclinical studies. They include taxoltere metro (2), the epothilones (3), and the BMS compounds 184476 and 188797 (4). This chapter will provide an overview of the current status of the taxanes and their combination with radiation in the treatment of human malignancy through a review of the preclinical literature on the subject. It will then focus on the status of clinical practice with a look into the future and the place of taxanes at the start of the new millennium.

Keywords

Esophageal Cancer Clin Oncol Maximum Tolerate Dose Radiat Oncol Biol Phys Weekly Paclitaxel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48: 353–374.PubMedCrossRefGoogle Scholar
  2. 2.
    Yang LX, Wang HJ, Holton RA. In vitro efficacy of a novel chemoradiopotentiator-taxoltere metro. Int J Radiat Oncol Biol Phys 2000; 46 (1): 159–163.PubMedCrossRefGoogle Scholar
  3. 3.
    Altmann KH, Wartmann M, O’Reilly T. Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000; 1470 (3): M79–91.PubMedGoogle Scholar
  4. 4.
    Rose WC, Fairchild C, Lee FY. Preclinical antitumor activity of two novel taxanes. Cancer Chemother Pharmacol 2001; 47 (2): 97–105.PubMedCrossRefGoogle Scholar
  5. 5.
    Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 1999; 54 (6A Suppl): 22–29.PubMedCrossRefGoogle Scholar
  6. 6.
    Rao S, Krauss NE, Heerding JM, et al. 3’-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem 1994; 269 (5): 3132–3134.PubMedGoogle Scholar
  7. 7.
    Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 1984; 25 (1): 83–125.PubMedCrossRefGoogle Scholar
  8. 8.
    Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32 (11): 2747–2755.PubMedCrossRefGoogle Scholar
  9. 9.
    Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83 (4): 288–291.PubMedCrossRefGoogle Scholar
  10. 10.
    Jordan MA, Wendell K, Gardiner S, Deny WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56 (4): 816–825.PubMedGoogle Scholar
  11. 11.
    Haldar S, Chintapalli J, Croce CM. Taxol induces Bc1–2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56 (6): 1253–1255.PubMedGoogle Scholar
  12. 12.
    Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996; 2 (1): 72–79.PubMedCrossRefGoogle Scholar
  13. 13.
    Vikhanskaya F, Vignati S, Beccaglia P, et al. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res 1998; 241(1):96–101.CrossRefGoogle Scholar
  14. 14.
    Zaffaroni N, Silvestrini R, Orlandi L, Bearzatto A, Gornati D, Villa R. Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. Br J Cancer 1998; 77 (9): 1378–1385.PubMedCrossRefGoogle Scholar
  15. 15.
    Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000; 88 (11): 2619–2628.PubMedCrossRefGoogle Scholar
  16. 16.
    Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56 (4): 816–825.PubMedGoogle Scholar
  17. 17.
    Taylor SS, McKeon F. Kinetochore localization of murine Bub 1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell 1997; 89 (5): 727–735.PubMedCrossRefGoogle Scholar
  18. 18.
    Taylor SS, Ha E, McKeon F. The human homologue of Bub3 is required for kinetochore localization of Bubl and a Mad3/Bubl-related protein kinase. J Cell Biol 1998; 142 (1): 1–11.PubMedCrossRefGoogle Scholar
  19. 19.
    Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272(27):17,118–17,125.Google Scholar
  20. 20.
    Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, Montegomrey W. Bc1–2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 1998; 13 (4): 839–848.PubMedGoogle Scholar
  21. 21.
    Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol 1998; 70 (3): 398–403.PubMedCrossRefGoogle Scholar
  22. 22.
    Huang Y, Ray S, Reed JC, et al. Estrogen increases intracellular p26Bc1–2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res Treat 1997; 42 (1): 73–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Huang Y, Ibrado AM, Reed JC, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997; 11 (2): 253–257.PubMedCrossRefGoogle Scholar
  24. 24.
    Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100 (5): 1282–1293.PubMedCrossRefGoogle Scholar
  25. 25.
    Panvichian R, Orth K, Day ML, Day KC, PilatMJ, Pienta KJ. Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res 1998; 58 (20): 4667–4672.PubMedGoogle Scholar
  26. 26.
    Rowinsky EK. The taxanes: dosing and scheduling considerations. Oncology (Huntingt) 1997; 11 (3 Suppl 2): 7–19.Google Scholar
  27. 27.
    Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8 (7): 1263–1268.PubMedGoogle Scholar
  28. 28.
    Huizing MT, Keung AC, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11 (11): 2127–2135.PubMedGoogle Scholar
  29. 29.
    Crown J, O’Leary M. The taxanes: an update. Lancet 2000 Apr 1; 355 (9210): 1176–1178.CrossRefGoogle Scholar
  30. 30.
    Nabholtz JM, North S, Smylie M, et al. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. Semin Oncol 2000; 27 (2 Suppl 3): 11–18.PubMedGoogle Scholar
  31. 31.
    Kaufman PA. Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer. Semin Oncol 1999; 26 (3 Suppl 8): 39–46.PubMedGoogle Scholar
  32. 32.
    Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000; 92 (9): 699–708.PubMedCrossRefGoogle Scholar
  33. 33.
    Schiller JH, Harrington D, Sandler A, et al. A Randomized Phase III Trial of Four Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer (NSCLC) (abstract 2). 2000. Pro Am Soc Clin Oncol 19: 1a.Google Scholar
  34. 34.
    Bellmunt J, Guillem V, Paz-Ares L, et al. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. Eur J Cancer 2000; 36 Suppl 2: 17–25.PubMedCrossRefGoogle Scholar
  35. 35.
    Choy H, Shyr Y, Cmelak AJ, Mohr PJ, Johnson DH. Patterns of practice survey for nonsmall-cell lung carcinoma in the U.S. Cancer 2000; 88 (6): 1336–1346.PubMedCrossRefGoogle Scholar
  36. 36.
    Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18 (10): 2095–2103.PubMedGoogle Scholar
  37. 37.
    Hall EJ. Radiobiology for the Radiobiologist Fourth Edition. J.B. Lippincott Company. Philadelphia. 1994.Google Scholar
  38. 38.
    Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 12–26.PubMedGoogle Scholar
  39. 39.
    Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992; 52 (12): 3495–3497.PubMedGoogle Scholar
  40. 40.
    Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD. Investigation of taxol as a potential radiation sensitizer. Cancer 1993; 71 (11): 3774–3778.PubMedCrossRefGoogle Scholar
  41. 41.
    Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 1995; 71 (6): 1194–1198.PubMedCrossRefGoogle Scholar
  42. 42.
    Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 1996; 56 (8): 1842–1850.PubMedGoogle Scholar
  43. 43.
    Amorino GP, Hamilton VM, Choy H. Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro. Radiat Oncol Investig 1999; 7 (6): 343–352.PubMedCrossRefGoogle Scholar
  44. 44.
    Creane M, Seymour CB, Colucci S, Mothersill C. Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer. Int J Radiat Biol 1999; 75 (6): 731–737.PubMedCrossRefGoogle Scholar
  45. 45.
    Mason KA, Kishi K, Hunter N, et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 1999; 5 (12): 4191–4198.PubMedGoogle Scholar
  46. 46.
    Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res 1995; 55 (16): 3564–3568.PubMedGoogle Scholar
  47. 47.
    Mason KA, Milas L, Peters LJ. Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa. Int J Radiat Oncol Biol Phys 1995; 32 (5): 1381–1389.PubMedCrossRefGoogle Scholar
  48. 48.
    Choy H. Taxanes in combined modality therapy for solid tumors. Crit Rev Oncol Hematol 2001; 37 (3): 237–247.PubMedCrossRefGoogle Scholar
  49. 49.
    Choy H. Combining taxanes with radiation for solid tumors. Int J Cancer 2000; 90 (3): 113–127.PubMedCrossRefGoogle Scholar
  50. 50.
    Choy H. Taxanes in combined-modality therapy for solid tumors. Oncology (Huntingt) 1999; 13 (10 Suppl 5): 23–38.Google Scholar
  51. 51.
    Dowell JE, Sinard R, Yardley DA, et al. Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 97–101.PubMedGoogle Scholar
  52. 52.
    Rathmann J, Leopold KA, Rigas JR, et al. Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 130–135.PubMedGoogle Scholar
  53. 53.
    Lau D, Ryu J, Gandara D, et al. Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 117–120.PubMedGoogle Scholar
  54. 54.
    Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12 (12): 2682–2686.PubMedGoogle Scholar
  55. 55.
    Socinski MA, Rosenman JG, Schell MJ, et al. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIAB nonsmall-cell lung carcinoma: a modified Phase I trial. Cancer 2000; 89 (3): 534–542.PubMedCrossRefGoogle Scholar
  56. 56.
    Kirkbride P, Gelmon K, Eisenhauer E, et al. Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: the Canadian experience. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 102–107.PubMedGoogle Scholar
  57. 57.
    Langer CJ. Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 108–116.PubMedCrossRefGoogle Scholar
  58. 58.
    Herscher LL, Hahn SM, Kroog G, et al. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J Clin Oncol 1998; 16 (2): 635–641.PubMedGoogle Scholar
  59. 59.
    Choy H, Safran H, Akerley W, et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 1998; 4 (8): 1931–1936.PubMedGoogle Scholar
  60. 60.
    Choy H, Akerley W, Safran H, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998; 16 (10): 3316–3322.PubMedGoogle Scholar
  61. 61.
    Choy H, Devore RF 3rd, Hande KR, et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 2000; 47 (4): 931–937.PubMedCrossRefGoogle Scholar
  62. 62.
    Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J, Doroshow J. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 2001; 19 (2): 442–447.PubMedGoogle Scholar
  63. 63.
    Choy H, LaPorte K, Knill-Selby E, et al. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 90–96.PubMedGoogle Scholar
  64. 64.
    Socinski MA, Halle J, Schell MJ, et al. Induction (I) and Concurrent (C) Carboplatin/Paclitaxel (C/P) with Dose-Escalated Thoracic Conformal Radiotherapy (TCRT) in Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC): A Phase I/II Trial. Proc Am Soc Clin Oncol 2000; 19: Abstract 1940.Google Scholar
  65. 65.
    Vokes EE, Leopold KA, Herndon JE, et al. CALGB Study 9431: A randomized phase study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer. Lung Cancer 2000; 29(S1):49(Abstract 158).CrossRefGoogle Scholar
  66. 66.
    Koukourakis MI, Bahlitzanakis N, Froudarakis M, et al. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIB non-small cell lung carcinoma. Br J Cancer 1999; 80: 1792–1796.PubMedCrossRefGoogle Scholar
  67. 67.
    Aamdal S, Lauvvang G, Owre K, et al. A phase VII study of docetaxel (Taxotere) combined with concurrent radiation therapy in locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2000; 29 (Suppl 1): 100 (abstract 327).CrossRefGoogle Scholar
  68. 68.
    Choy H, DeVore RF, Porter LL, et al. Phase I trial of outpatient weekly docetaxel (DTX) Carboplatin (CBDCA) and concurrent thoracic radiation therapy (TRT) for stage III unresectable non-small-cell lung cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Pro Am Soc Clin Oncol 1999; 18: 475a (abstract 1833).Google Scholar
  69. 69.
    Murakami H, Kubota K, Ohe Y, et al. Phase I study of weekly docetaxel (DTX) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) for stage III non-small cell lung cancer (NSCLC). Lung Cancer 2000; 29 (Suppl 1): 111 (abstract 367).CrossRefGoogle Scholar
  70. 70.
    Segawa Y, Ueoka H, Kiura K, et al. A phase I/II study of docetaxel (TXT) and cisplatin (CDDP) with concurrent thoracic radiotherapy (TRT) for locally advanced non-small-cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol 2000; 19: 508a.Google Scholar
  71. 71.
    Nyman J, Mercke C. Accelerated radiotherapy with docetaxel and cisplatin as induction and concomitant chemotherapy for stage III non-small cell lung cancer. Lung Cancer 2000; 29 (Suppl 1): 98.CrossRefGoogle Scholar
  72. 72.
    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10 (6): 890–895.PubMedGoogle Scholar
  73. 73.
    Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327 (23): 1618–1624.PubMedCrossRefGoogle Scholar
  74. 74.
    Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340 (4): 265–271.PubMedCrossRefGoogle Scholar
  75. 75.
    Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993; 11 (2): 336–344.PubMedGoogle Scholar
  76. 76.
    Ettinger DS. Concurrent paclitaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 148–150.PubMedGoogle Scholar
  77. 77.
    Levitan N, Dowlati A, Shina D, et al. Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol 2000; 18 (5): 1102–1109.PubMedGoogle Scholar
  78. 78.
    Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, Thomas M, Greco FA. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 1997; 15 (12): 3464–3470.PubMedGoogle Scholar
  79. 79.
    Bremnes RM, Sundstrom S, Aasebo U, Vilsvik J. Paclitaxel in combination with cisplatin, etoposide and thoracic radiotherapy for limited stage small cell lung cancer (SCLC): a phase II study (abstract 1826). Pro Am Soc Clin Oncol 1998; 17: 475a.Google Scholar
  80. 80.
    Glantz MJ, Chamberlain MC, Chang SM, Prados MD, Cole BF. The role of paclitaxel in the treatment of primary and metastatic brain tumors. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 27–33.PubMedGoogle Scholar
  81. 81.
    Glantz MJ, Choy H, Kearns CM, Akerley W, Egorin MJ. Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Semin Oncol 1995; 22 (5 Suppl 12): 26–32.PubMedGoogle Scholar
  82. 82.
    Glantz MJ, Choy H, Kearns CM, et al. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults astrocytomas. J Clin Oncol 1996; 14 (2): 600–609.PubMedGoogle Scholar
  83. 83.
    Glantz MJ, Choy H, Kearns CM, et al. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 1995; 87 (14): 1077–1081.PubMedCrossRefGoogle Scholar
  84. 84.
    Lederman G, Arbit E, Odaimi M, Wertheim S, Lombardi E. Recurrent glioblastoma multiforme: potential benefits using fractionated stereotactic radiotherapy and concurrent taxol. Stereotact Funct Neurosurg 1997; 69 (1–4 Pt 2): 162–174.PubMedCrossRefGoogle Scholar
  85. 85.
    Lederman G, Arbit E, Odaimi M, Lombardi E, Wrzolek M, Wronski M. Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: a preliminary report. Int J Radiat Oncol Biol Phys 1998; 40 (3): 661–666.PubMedCrossRefGoogle Scholar
  86. 86.
    Wehbe T, Glantz M, Choy H, Glantz L, Cortez S, Akerley W 3rd, Mills P, Cole B. Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas. J Neurooncol 1998; 39 (3): 245–251.PubMedCrossRefGoogle Scholar
  87. 87.
    Langer CJ, Paulus R, Ruffer J, Movsas B, Murray K, Rhodes H, Curran WJ. Pro Am Soc Clin Oncol. Phase II RTOG Trial of Weekly Paclitaxel (TAX) and Conventional External Beam Radiation Therapy for Supratentorial Glioblastoma Mutiforme (abstract 534 ) 1999. 18.Google Scholar
  88. 88.
    Julka PK, Awasthy BS, Rath GK, Agarwal S, Varna T, Mahapatra AK, Singh R. A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme. Australas Radiol 2000; 44 (1): 84–87.PubMedCrossRefGoogle Scholar
  89. 89.
    Fountzilas G, Karavelis A, Capizzello A, Kalogera-Fountzila A, Karkavelas G, Zamboglou N, Selviaridis P, Foroglou G, Tourkantonis A. Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study. J Neurooncol 1999; 45 (2): 159–165.PubMedCrossRefGoogle Scholar
  90. 90.
    Forsyth P, Cairncross G, Stewart D, Goodyear M, Wainman N, Eisenhauer E. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 1996; 14 (2): 203–206.PubMedCrossRefGoogle Scholar
  91. 91.
    Herrington JD, Di Nunno L, Rinehart JJ. Lack of CNS penetration of docetaxel in a patient with leptomeningeal carcinomatosis. Ann Pharmacother 1998; 32 (5): 611–612.PubMedCrossRefGoogle Scholar
  92. 92.
    Koukourakis MI, Giatromanolaki A, Schiza S, Kakolyris S, Georgoulias V. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation. Int JRadiat Oncol Biol Phys 1999; 43 (1): 107–114.CrossRefGoogle Scholar
  93. 93.
    Kim HL, Steinberg GD. The current status of bladder preservation in the treatment of muscle invasive bladder cancer. J Urol 2000; 164 (3 Pt 1): 627–632.PubMedGoogle Scholar
  94. 94.
    Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14 (11): 2901–2907.PubMedGoogle Scholar
  95. 95.
    Varveris H, Delakas D, Anezinis P, et al. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control. Anticancer Res 1997; 17 (6D): 4771–4780.PubMedGoogle Scholar
  96. 96.
    Dunst J, Weigel C, Heynemann H, Becker A. Preliminary results of simultaneous radiochemotherapy with paclitaxel for urinary bladder cancer. Strahlenther Onkol 1999; 175 Suppl 3: 7–10.Google Scholar
  97. 97.
    Nichols RC Jr, Sweetser MG, Mahmood SK, Malamud FC, Dunn NP, Adams JP, Kyker JS, Lydick K. Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combination. Int J Cancer 2000; 90 (5): 281–286.PubMedCrossRefGoogle Scholar
  98. 98.
    RTOG 9906. A Phase I/II Trial in Patients with Muscle-Invading Bladder Cancer of Transurethral Surgery Plus Taxol, Cisplatin and BID Irradiation Followed by Either Selective Bladder Preservation or Radical Cystectomy and Adjuvant Chemotherapy. Study Protocol.Google Scholar
  99. 99.
    Peters WA, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18 (8): 1606–1613.PubMedGoogle Scholar
  100. 100.
    Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340 (15): 1154–1161.PubMedCrossRefGoogle Scholar
  101. 101.
    Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340 (15): 1137–1143.PubMedCrossRefGoogle Scholar
  102. 102.
    Chen MD, Paley PJ, Potish RA, Twiggs LB. Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. Gynecol Oncol 1997; 67 (2): 131–136.PubMedCrossRefGoogle Scholar
  103. 103.
    Bruzzone M, Franzone P, Ghione G, et al. Combined Treatment with Paclitaxel (P) and Radiotherapy (RT) in Patients (Pts) with Advanced Cervical Cancer (ACC) (abstract 1592). Pro Am Soc Clin Oncol 2000; 19.Google Scholar
  104. 104.
    De Palo G, Cerrotta A, Gardani G, et al. Concurrent Radiotherapy and Taxol as Radiosensitizer in Locally Advanced or Recurrent Carcinoma of the Uterine Cervix (abstract 1404). Pro Am Soc Clin Oncol 1998; 17: 364a.Google Scholar
  105. 105.
    GOG-9803 Phase I/II Study of Radiotherapy Combined With Paclitaxel and Cisplatin in Patients With Stage IB2, IIA, IIB, IIIB, or IVA Invasive Carcinoma of the Cervix.Google Scholar
  106. 106.
    GOG-9804 Phase I/II Study of Extended Field Radiation Therapy With Concurrent Paclitaxel and Cisplatin Chemotherapy in Patients With Previously Untreated Carcinoma of the Cervix Metastatic to the Para-aortic Lymph Nodes. Study Protocol. http://www.cancer.gov/search/clinical_trialsGoogle Scholar
  107. 107.
    Frigerio L, Mangili G, Aletti G, Carnelli M, Garavaglia E, Beatrice S, Ferrari A. Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study. Gynecol Oncol 2001; 81 (1): 53–57.PubMedCrossRefGoogle Scholar
  108. 108.
    Formenti SC, Symmans WF, Volm M, et al. Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 34–42.PubMedGoogle Scholar
  109. 109.
    Skinner KA, Silberman H, Florentine B, et al. Preoperative paclitaxel and radiotherapy for locally advanced breast cancer: surgical aspects. Ann Surg Oncol 2000; 7 (2): 145–149.PubMedCrossRefGoogle Scholar
  110. 110.
    Bellon JR, Lindsley KL, Ellis GK, Gralow JR, Livingston RB, Austin Seymour MM. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys 2000; 48 (2): 393–397.PubMedCrossRefGoogle Scholar
  111. 111.
    Mauer AM, Masters GA, Haraf DJ, et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1988; 16: 159–164.Google Scholar
  112. 112.
    Blanke CD, Choy H, Teng M, et al. Concurrent paclitaxel and thoracic irradiation for locally advanced esophageal cancer. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 43–52.PubMedGoogle Scholar
  113. 113.
    Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. DAMA 1999; 281 (17): 1623–1627.Google Scholar
  114. 114.
    Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339 (27): 1979–1984.PubMedCrossRefGoogle Scholar
  115. 115.
    Burmeister BH, Denham JW, O’Brien M, et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. Int J Radiat Oncol Biol Phys 1995; 32 (4): 997–1006.PubMedCrossRefGoogle Scholar
  116. 116.
    Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335 (7): 462–467.PubMedCrossRefGoogle Scholar
  117. 117.
    Wright CD, Wain JC, Lynch TJ, et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg 1997; 114 (5): 811–815.PubMedCrossRefGoogle Scholar
  118. 118.
    Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001; 19 (1): 1–7.PubMedCrossRefGoogle Scholar
  119. 119.
    Meluch AA, Hainsworth JD, Gray JR, et al. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am 1999; 5 (2): 84–91.PubMedGoogle Scholar
  120. 120.
    Schnirer II, Komaki R, Yao JC, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol 2001; 24 (1): 91–95.PubMedCrossRefGoogle Scholar
  121. 121.
    Adelstein DJ, Rice TW, Rybicki LA, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000; 18 (10): 2032–2039.PubMedGoogle Scholar
  122. 122.
    Thirion P, Piedbois Y, Adelstein DJ. (2001). Preoperative Chemoradiotherapy Using Taxanes for Locally Advanced Esophageal Carcinoma. J Clin Oncol 2001; 19: 1880–1882.Google Scholar
  123. 123.
    Safran H, Akerman P, Cioffi W, et al. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 53–57.PubMedGoogle Scholar
  124. 124.
    Safran H, King TP, Choy H, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J Clin Oncol 1997; 15 (3): 901–907.PubMedGoogle Scholar
  125. 125.
    Safran H, Moore T, lannitti D, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2001; 49 (5): 1275–1279.PubMedCrossRefGoogle Scholar
  126. 126.
    Safran H, Wanebo HJ, Hesketh PJ, et al. Paclitaxel and concurrent radiation for gastric cancer. Int J Radiat Oncol Biol Phys 2000; 46 (4): 889–894.PubMedCrossRefGoogle Scholar
  127. 127.
    Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995; 71 (1): 83–91.PubMedCrossRefGoogle Scholar
  128. 128.
    El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 1996; 14 (3): 838–847.PubMedGoogle Scholar
  129. 129.
    Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355 (9208): 949–955.PubMedGoogle Scholar
  130. 130.
    Rosenthal DI, Lee JH, Sinard R, et al. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2001; 19 (5): 1363–1373.PubMedGoogle Scholar
  131. 131.
    Sunwoo JB, Herscher LL, Kroog GS, et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 2001; 19 (3): 800–811.PubMedGoogle Scholar
  132. 132.
    Machtay M, Aviles V, Kligerman MM, et al. A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unresectable head and neck cancer. Int J Radiat Oncol Biol Phys 1999; 44 (2): 311–315.PubMedCrossRefGoogle Scholar
  133. 133.
    Steinberg L, Hassan M, Olmsted L, et al. A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma. Semin Oncol 1997; 24(6 Suppl 19):S19–51-S19–56.Google Scholar
  134. 134.
    Amrein PC, McIntyre J, Colevas AD, Wang CC, Varvares M, Fabian. A phase I trial of concurrent taxol and Bid radiotherapy with and without ethyol in patients with advanced squamous cell carcinoma of the head and neck. (abstract 1651) Pro Am Soc Clin Oncol 2000; 19: 418a.Google Scholar
  135. 135.
    Suntharalingam M, Haas ML, Conley BA, et al. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2000; 47 (1): 49–56.PubMedCrossRefGoogle Scholar
  136. 136.
    Suntharalingam M, Haas ML, Van Echo DA, et al. Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer 2001; 91 (3): 548–554.PubMedCrossRefGoogle Scholar
  137. 137.
    Eckardt A, Wildfang I, Karstens JH. Simultaneous radiochemotherapy with taxol/carboplatin in advanced operable head-neck tumors. Preliminary results. Strahlenther Onkol 1999; 175 Suppl 3: 11–13.Google Scholar
  138. 138.
    Eckardt A, Wildfang I, Rades D, et al. Mulicenter phase II study of preoperative concurrent paclitaxel, carboplatin and radiotherapy in stage HI/IV resectable cancer of the oropharynx and oral cavity: an interim analysis (abstract 1658). Pro Am Soc Clin Oncol 2000; 19: 420a.Google Scholar
  139. 139.
    Kies ME, Haraf D, Rosen F, Stenson K, List M, Brockstein B, Chung T, Mittal B, Pelzer H, Portugal L, Rademaker A, Weichselbaum R, Vokes EE. Concomitant Infusional Paclitaxel and Fluorouracil, Oral Hydroxyurea, and Hyperfractionated Radiation for Locally Advanced Squamous Head and Neck Cancer. J Clin Oncol 2001; 19: 1961–1969.PubMedGoogle Scholar
  140. 140.
    Hesse K, Heinrich B, Zimmermann F, et al. Combined radiochemotherapy with docetaxel in patients with unresectable locally advanced head and neck tumors. Strahlenther Onkol 2000; 176 (2): 67–72.PubMedCrossRefGoogle Scholar
  141. 141.
    Koukourakis MI, Bizakis JG, Skoulakis CE, et al. Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study. Anticancer Res 1999; 19 (3B): 2305–2309.PubMedGoogle Scholar
  142. 142.
    Colevas AD, Busse PM, Norris CM, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase UII trial. J Clin Oncol 1998; 16 (4): 1331–1339.PubMedGoogle Scholar
  143. 143.
    Tishler RB, Posner MR, Colevas AD, et al. Phase I study of concurrent taxotere/radiation after induction chemotherapy in patients with squamous cell cancer of the head and neck (abstract 1547). Pro Am Soc Clin Oncol 1999; 18: 400a.Google Scholar
  144. 144.
    Glantz MJ, Choy H, Chakravarthy A, et al. A randomized phase III trial of concurrent paclitaxel and whole brain radiotherapy (WBRT/) vs. WBRT alone for brain metastases. Pro Am Soc Clin Oncol 1999; 19: 140a.Google Scholar
  145. 145.
    Ferrante K, Winograd B, Canetta R. Promising new developments in cancer chemotherapy. Cancer Chemother Pharmacol 1999; 43 (Suppl): S61 - S68.PubMedCrossRefGoogle Scholar
  146. 146.
    Menendez A, Laidlaw J, Raventos-Suarez C, et al. In vitro characterization of BMS-184476, a novel taxane with promising preclinical activity. Proc Am Assoc Cancer Res 2000; 41: 554 (abstract 3529).Google Scholar
  147. 147.
    Highely M, Sessa C, Hughes A, et al. Phase I and pharmacokinetic (PK) study of BMS-184476, a new taxanes analog, given weekly in patients with advanced malignancies. Proc Am Soc Clin Oncol 1999; 18: 168a (abstract 644).Google Scholar
  148. 148.
    Hidalgo M, Aylesworth C, Ferrante K, et al. Phase I and pharmacokinetic (PK) study of BMS-184476, a potent and soluble taxane analog, as a 1-hour infusion every 3 weeks. Proc Am Soc Clin Oncol 1999; 18: 168a (abstract 645).Google Scholar
  149. 149.
    Stevenson JP, Gallagher M, Sun W, et al. Phase I clinical and pharmacokinetic study of the taxanes analog BMS-184476 administered as a 1-hour iv infusion in combination with carboplatin every 21 days. Proc Am Assoc Cancer Res 2000; 41: 608 (abstract 3871).Google Scholar
  150. 150.
    Advani R, Fischer GA, Jambalos C, et al. Phase I study of BMS-188797, a new taxane analog administered weekly in patients with advanced malignancies (abstract 422). Pro Am Soc Clin Oncol 2001; 20: 106a.Google Scholar
  151. 151.
    Rose WC, Lee FYF, Golik J, et al. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative. Cancer Chemother Pharmacol 2000; 46: 246–250.PubMedCrossRefGoogle Scholar
  152. 152.
    Trump DL, Egorin M, Ramanathan R, et al. A novel oral taxane (BMS-275183): a phase I trial with evaluation of pharmacokinetics, pharmacodynamics and bioavailability.Google Scholar
  153. 153.
    Nicoletti MI, Colombo T, Rossi C, et al. IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res 2000; 60 (4): 842–846.PubMedGoogle Scholar
  154. 154.
    Gallo D, Ferlini C, Distefano M, et al. Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer. Cancer Chemother Pharmacol 2000; 45 (2): 127–132.PubMedCrossRefGoogle Scholar
  155. 155.
    Ferlini C, Distefano M, Pignatelli F, et al. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors. Br J Cancer 2000; 83 (12): 1762–1768.PubMedCrossRefGoogle Scholar
  156. 156.
    Tortora G, Caputo R, Damiano V, et al. Specific Inhibition of EGFR Tyrosine Kinase with ZD1839 (’Iressa’) Combined with a Protein Kinase a Antisense and the Novel Taxane IDN5109 Causes Cooperative Inhibition of Tumour Growth and Angiogenesis. Proceedings of the AACR,Vol. 42, March 2001. abstract 4315.Google Scholar
  157. 157.
    Taraboletti G, Gatto C, Riva A, et al. Anti-Angiogenic and Anti-Metastatic Activity of IDN 5390, a New C-Seco Taxane Derivative. Proceedings of the AACR,Vol. 42, March 2001. abstract 3162.Google Scholar
  158. 158.
    Vrignaud P, Lejeune P, Bissery MC. TXD258, a New Taxoid, with Oral Antitumor Activity. Proceedings of the AACR, Vol. 42, March 2001. Abstract 1975.Google Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Robert M. MacRae
  • Hak Choy

There are no affiliations available

Personalised recommendations